Shares of Pharming Group jumped nearly 10% today after the Dutch rare-disease biotech disclosed preliminary third-quarter revenue that blew past analyst forecasts — and then pulled its full earnings report forward by more than a week, a move companies typically make only when they have good news to share.
Both Key Drugs Delivered, but for Different Reasons
Total Q3 revenue came in at roughly US$117.6 million, up 21% from US$97.3 million a year earlier, driven by strong performance from both of Pharming's marketed products.
RUCONEST, a treatment for acute hereditary angioedema attacks, contributed about US$93.8 million — up 14% year-over-year and 30% from Q2 — while Joenja, a therapy for a rare immune disorder called APDS, added US$23.8 million, surging 58% from the prior year. That's a dramatic reversal from a first half where RUCONEST revenue fell 12% in the first six months of 2026 versus 2025.
A Closer Look Reveals Some One-Time Tailwinds Investors should note asterisks. Pharming acknowledged that RUCONEST's strong quarter partly reflected an early seasonal inventory build at a single U.S. specialty pharmacy — meaning some of that revenue may have been pulled forward from Q4. Joenja's international sales similarly benefited from "temporary" ordering patterns abroad. When one-time stocking effects fade, the underlying growth rate matters more.
Tighter Guidance Signals Confidence — and a Lower Ceiling
Pharming narrowed its 2026 revenue guidance from US$375–$395 million to US$380–$390 million, and cut operating expense guidance from US$315–$320 million to US$310–$315 million. The floor rose $5 million, reassuring, but the ceiling dropped by the same amount. Notably, initial 2026 guidance issued in Q1 was US$405–$425 million — the midpoint has fallen roughly $30 million across two revisions. That cost discipline, however, is real: Q3 operating expenses of ~US$74.6 million were essentially flat year-over-year, evidence of "efficient scaling."
What October 27 Needs to Show
Full Q3 results arrive October 27, pulled forward from November 5 after results exceeded consensus. Investors will scrutinize Joenja's patient enrollment trajectory and whether RUCONEST's U.S. demand recovery is durable beyond inventory restocking. At a trailing P/E of roughly 78x and a $678 million market cap, the stock is priced for sustained growth — not one good quarter.